Diabetics on dialysis in Italy: A nationwide epidemiological study

Nephrology Dialysis Transplantation

Volumn 23, Issue 12, 2008, Pages 3988-3995

  Panzetta, Giovanni ^a   Basile, Carlo ^b,g   Santoro, Antonio ^c   Ancarani, Enzo ^d   Costantini, Stefano ^d   Guarnieri, Francesco ^e   Verzetti, Giuseppe ^f  

^a UNIVERSITY HOSPITAL OF TRIESTE   (Italy)

^b MIULLI GENERAL HOSPITAL   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d BELCOLLE HOSPITAL   (Italy)

^e Hospal SpA   (Italy)

^f MAGGIORE DELLA CARITÀ HOSPITAL   (Italy)

^g NONE   (Italy)

Author keywords

Diabetes mellitus; Dialysis treatment; Epidemiology; Pharmacological therapy; Survey

Indexed keywords

ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; BICARBONATE; CALCIUM ANTAGONIST; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; NITRIC ACID DERIVATIVE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROSCLEROTIC PLAQUE; CATHETER INFECTION; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CORONARY ARTERY OBSTRUCTION; DIABETIC PATIENT; DIALYSIS; DISEASE SEVERITY; DOPPLER ECHOCARDIOGRAPHY; ECHOCARDIOGRAPHY; EPIDEMIC; FEMALE; GLUCOSE BLOOD LEVEL; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIALYSIS PATIENT; HUMAN; INDUSTRIALIZATION; INSULIN DEPENDENT DIABETES MELLITUS; ITALY; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT CARE; PATIENT EDUCATION; PERITONEAL DIALYSIS; PERITONEUM; PREVALENCE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; ITALY; MALE; MIDDLE AGED; NUTRITIONAL STATUS; QUESTIONNAIRES; RENAL DIALYSIS;

EID: 56749092202     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn413     Document Type: Article

References (46)

1. US Renal Data System: 2005 Report. Am J Kidney Dis 2006; 47 (Suppl 1): S65-S80
2. ERA-EDTA Registry. 2005 Annual Report. Academic Medical Center, Department of Medical Informatics, Amsterdam, The Netherlands, 2007
3. Ritz E, Rychlik I, Locatelli F et al. End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999; 34: 795-808
4. Locatelli F, Canaud B, Eckardt KU. The importance of diabetic nephropathy in current nephrological practice. Nephrol Dial Transplant 2003; 18: 1716-1725
5. Stack AG, Bloembergen WE. Prevalence and clinical correlates of coronary artery disease among new dialysis patients in the United States: a cross-sectional study. J Am Soc Nephrol 2001; 12: 1516-1523
6. Johnson JG, Gore SM, Firth J. The effect of age, diabetes, and other comorbidity on the survival of patients on dialysis: a systematic quantitative overview of the literature. Nephrol Dial Transplant 1999; 14: 2156-2164
7. Okuno S, Ishimura E, Kim M et al. Changes in body fat mass in male hemodialysis patients: a comparison between diabetics and nondiabetics. Am J Kidney Dis 2001; 38(Suppl 1): S208-S211
8. Brunner FP, Brynger H, Challah S et al. Renal replacement therapy in patients with diabetic nephropathy, 1980-1985 Registry Report. Nephrol Dial Transplant 1988; 3: 585-595
9. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998; 351: 1755-1762
10. Gaede P, Vedel P, Parving HH et al. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the steno type 2 randomized study. Lancet 1999; 353: 617-622
11. Gaede P, Vedel P, Larsen N et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393
12. Nissen SE, Tuzcu EM, Schoenhagen P et al. Effect of intensive compared to moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004; 291: 1071-1080
13. Hayashino Y, Fukuhara S, Akiba T et al. Diabetes, glycemic control and mortality risk in patients on hemodialysis: the Japan Dialysis Outcomes and Practice Pattern Study. Diabetologia 2007; 50: 1170-1177
14. McMurray SD, Johnson G, Davis S et al. Diabetes education and care management significantly improve patient outcomes in the dialysis unit. Am J Kidney Dis 2002; 40: 566-575
15. Flauto RP, Leon JB, Sehgal AR. The provision and outcomes of diabetic care of hemodialysis patients. Am J Kidney Dis 2003; 41: 125-131
16. Sorensen VR, Mathiesen ER, Watt T et al. Diabetic patients treated with dialysis: complications and quality of life. Diabetologia 2007; 50: 2254-2262
17. NKF-K/DOQI. Clinical practice guidelines for hemodialysis adequacy. Am J Kidney Dis 2006; 48(Suppl 1): S2-S90
18. European Best Practice Guidelines for Haemodialysis. Available at http://ndt.oxfordjournals.org/content/vol17_7/index.dtl
19. Verzetti G, Navino G, Bolzani R et al. Acetate-free biofiltration versus bicarbonate haemodialysis in the treatment of patients with diabetic nephropathy: a cross-over multicentric study. Nephrol Dial Transplant 1998; 13: 955-961
20. Movilli E, Camerini C, Zein H et al. A prospective comparison of bicarbonate dialysis, hemodiafiltration, and acetate-free biofiltration in the elderly. Am J Kidney Dis 1995; 27: 541-547
21. Todeschini M, Macconi D, Ferǹandez NG et al. Effect of acetate-free biofiltration and bicarbonate hemodialysis on neutrophil activation. Am J Kidney Dis 2002; 40: 783-793
22. Rabindranath KS, Strippoli GFM, Roderick P et al. Comparison of hemodialysis, hemofiltration, and acetate-free biofiltration for ESRD: systematic review. Am J Kidney Dis 2005; 45: 437-447
23. Lederer SR, Schiffl H. Ultrapure dialysis fluid lowers the cardiovascular morbidity in patients on maintenance hemodialysis by reducing continuous microinflammation. Nephron 2002; 91: 452-455
24. Panichi V, Migliori M, De Pietro S et al. The link of biocompatibility to cytokine production. Kidney Int 2000; 58(Suppl 76): S96-S103
25. Caglar C, Peng Y, Pupim LB et al. Inflammatory signals associated with hemodialysis. Kidney Int 2002; 62: 1408-1416
26. Carracedo J, Ramirez R, Madueño JA et al. Cell apoptosis and hemodialysis-induced inflammation. Kidney Int 2002; 61: 89-93
27. Bouré; T, Vanholder R. Which dialyser membrane to choose? Nephrol Dial Transplant 2004; 19: 293-296
28. Wanner C, Bahner U, Mattern R et al. Effect of dialysis flux and membrane material on dyslipidaemia and inflammation in hemodialysis patients. Nephrol Dial Transplant 2004; 19: 2570-2575
29. Chauveau P, Nguyen H, Combe C et al. Dialyzer membrane permeability and survival in hemodialysis patients. Am J Kidney Dis 2005; 45: 565-571
30. Carracedo J, Merino A, Nogueras S et al. On line hemodiafiltration reduces the proinflammatory CD14 and CD16 monocyte-derived dendritic cells: a prospective, crossover study. J Am Soc Nephrol Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (from the American Diabetes Association). Diabetes Care 2003; 26(Suppl 1): S5-S20
31. Gavin TR, Alberti KG, Davison MB et al. Report of the Expert Commitee on the Diagnosis and Classification of Diabetes Mellitus (from the American Diabetes Association). Diabetes Care 2003; 26(Suppl 1): S5-S20
32. Williams ME, Lacson E Jr, Teng M et al. Hemodialyzed type I and type II diabetic patients in the US: characteristics, glycemic control, and survival. Kidney Int 2006; 70: 1503-1509
33. Catalano C, Postorino M, Kelly PJ et al. Diabetes mellitus and renal replacement therapy in Italy: prevalence, main characteristics and complications. Nephrol Dial Transplant 1990; 5: 788-796
34. Van Dijk PC, Jager KJ, Stengel B et al. Renal replacement therapy for diabetic end-stage renal disease: data from 10 registries in Europe (1991-2000). Kidney Int 2005; 67: 1489-1499
35. Sorensen VR, Mathiesen ER, Heaf J et al. Improved survival rate in patients with diabetes and end-stage renal disease in Denmark. Diabetologia 2007; 50: 922-929
36. Stel VS, van Dijk PC, van Manen JG et al. Prevalence of co-morbidity in different European RRT populations and its effect on access to renal transplantation. Nephrol Dial Transplant 2005; 20: 2803-2811
37. Ritz E, Stefanski A. Diabetic nephropathy in type II diabetes. Am J Kidney Dis 1996; 27: 167-194
38. Schrier RW. Treating high-risk diabetic hypertensive patients with comorbid conditions. Am J Kidney Dis 2000; 36(Suppl 1): S10-S17
39. Canaud B, Chènine L, Formet C et al. Hemodialysis as renal replacement therapy of choice for diabetic patients. Nephrol Dial Transplant 2006; 21(Suppl 1): S86-S93
40. Nolph KD. Clinical results with peritoneal dialysis - registry experiences. In Twardowski ZJ, Nolph KD, Khanna R (eds). Contemporary Issues in Nephrology. Peritoneal Dialysis. New York: Churchill Livingstone, 1990, 127-144
41. Fenton SS, Schaubel DE, Desmeules M et al. Hemodialysis versus peritoneal dialysis: a comparison of adjusted mortality rates. Am J Kidney Dis 1997; 30: 334-342
42. Lee HB, Chung SH, Chu WS et al. Peritoneal dialysis in diabetic patients. Am J Kidney Dis 2001; 38(Suppl 1): S200-S203
43. Issad B, Deray G. Peritoneal dialysis as prime treatment for diabetic patients with ESRD. Nephrol Ther 2006; 2(Suppl 1): S94-S102
44. Quellhorst E. Insulin therapy during peritoneal dialysis: pros and cons of various forms of administration. J Am Soc Nephrol 2003; 13: 93-96
45. Johnson CA, Amidon G, Reicher JE et al. Absorption of insulin to the surface of peritoneal dialysis solutions containers. Am J Kidney Dis 1983; 3: 224-228
46. Icks A, Rathmann W, Haaster B et al. KORA Studiengruppe. Dtsch Med Wochenschr 2006; 131: 73-78